Stocktoria

Metagenomi Therapeutics, Inc. MGX

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-02-09

Metagenomi Therapeutics, Inc. statistics & valuation

Market cap$47.1M
P / S1.9×
P / B0.3×
Net margin-348.5%
Return on equity-55.4%
FCF margin-354.9%
Return on capital-48.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-152.50% -149.30% -348.50% 202320242025
Gross margin (%)
202320242025
Operating margin (%)
-175.40% -170.00% -380.90% 202320242025
Return on equity (%)
-33.20% -55.40% 202320242025
Shares outstanding
3.4M 37.4M 37.6M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-18.70% -24.00% -39.70% 202320242025
Free cash flow margin (%)
-226.20% -214.50% -354.90% 202320242025
Debt / equity (×)
202320242025
EPS ($)
-$20.05 -$2.36 -$2.36 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Operating margin-380.9%-170.0%-175.4%
Net margin-348.5%-149.3%-152.5%
FCF margin-354.9%-214.5%-226.2%
Return on assets-39.7%-24.0%-18.7%
Return on equity-55.4%-33.2%50.3%
Current ratio7.226.914.04

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.